<DOC>
	<DOCNO>NCT00097383</DOCNO>
	<brief_summary>This non-randomized Phase 2 portion study test ALIMTA epirubicin combination locally advance metastatic breast cancer . Epirubicin well-established drug therapy breast cancer . Both ALIMTA epirubicin combine drug yet combine . It expect patient benefit different mechanism action two drug .</brief_summary>
	<brief_title>Study Alimta Epirubicin Administered Patients With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Diagnosis locally advance metastatic breast cancer amenable local treatment . Patients must chemonaive neoadjuvant and/or adjuvant chemotherapy . Patients must least one measurable lesion area previously irradiate . No chemotherapy least 4 week prior study enrollment . Signed informed consent patient . Treatment drug within last 30 day receive regulatory approval . Serious systemic disorder , include active infection . Significant cardiovascular disease . Pregnancy breast feed . Inability unwillingness take folic acid Vitamin B12 supplementation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>